An update on topical haemostatic agents in liver surgery: systematic review and meta analysis

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 23, Issue 10, 2016, Pages 609-621

  Brustia, Raffaele ^a,b   Granger, Benjamin ^a,b   Scatton, Olivier ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Bile leak; Blood loss; Liver surgery; Topical haemostatic agents

Indexed keywords

BIOMATERIAL; BOVINE SERUM ALBUMIN; CELLULOSE; COLLAGEN; CYANOACRYLATE; FIBRIN GLUE; FIBRINOGEN; GELATIN; GLUTARALDEHYDE; HEMOSTATIC AGENT; MACROGOL; POLYSACCHARIDE; SERUM ALBUMIN; THROMBIN;

BILE; BLEEDING; BLOOD TRANSFUSION; CASE CONTROL STUDY; COHORT ANALYSIS; HEMOSTASIS; HUMAN; LAPAROSCOPIC SURGERY; LIVER SURGERY; LIVER TRANSPLANTATION; META ANALYSIS; MORBIDITY; MORTALITY; OPERATIVE BLOOD LOSS; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SURGICAL SPONGE;

EID: 84990178454     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.389     Document Type: Review

References (49)

1. Dokmak S, Ftériche FS, Borscheid R, Cauchy F, Farges O, Belghiti J. Liver resections in the 21st century: we are far from zero mortality. HPB (Oxford). 2013;15:908–915.
2. Virani S, Michaelson JS, Hutter MM, Lancaster RT, Warshaw AL, Henderson WG, et al. Morbidity and mortality after liver resection: results of the patient safety in surgery study. J Am Coll Surg. 2007;204:1284–1292.
3. Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Yamashita K, et al. Perioperative management of hepatic resection toward zero mortality and morbidity: analysis of 793 consecutive cases in a single institution. J Am Coll Surg. 2010;211:443–449.
4. Cauchy F, Aussilhou B, Dokmak S, Fuks D, Gaujoux S, Farges O, et al. Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Ann Surg. 2012;256:746–752.
5. Page AJ, Gani F, Crowley KT, Lee KH, Grant MC, Zavadsky TL, et al. Patient outcomes and provider perceptions following implementation of a standardized perioperative care pathway for open liver resection. Br J Surg. 2016;103:564–571.
6. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–466.
7. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–2072.
8. Zaydfudim VM, Kerwin MJ, Turrentine FE, Bauer TW, Adams RB, Stukenborg GJ. The impact of chronic liver disease on the risk assessment of ACS NSQIP morbidity and mortality after hepatic resection. Surgery. 2016;159:1308–1315.
9. Hallet J, Kulyk I, Cheng ES, Truong J, Hanna SS, Law CH, et al. The impact of red blood cell transfusions on perioperative outcomes in the contemporary era of liver resection. Surgery. 2016;159:1591–1599.
10. Kooby DA, Stockman J, Ben-Porat L, Gonen M, Jarnagin WR, Dematteo RP, et al. Influence of transfusions on perioperative and long-term outcome in patient following hepatic resection for colorectal metastases. Ann Surg. 2003;237:860–869.
11. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: A 20-year experience. Ann Surg. 2011;253:745–758.
12. Ibrahim S, Chen CL, Lin CC, Yang CH, Wang CC, Wang SH, et al. Intraoperative blood loss is a risk factor for complications in donors after living donor hepatectomy. Liver Transpl. 2006;12:950–957.
13. Weeder PD, Porte RJ, Lisman T. Hemostasis in liver disease: implications of new concepts for perioperative management. Transfus Med Rev. 2014;28:107–113.
14. Tympa A, Theodoraki K, Tsaroucha A, Arkadopoulos N, Vassiliou I, Smyrniotis V. Anesthetic considerations in hepatectomies under hepatic vascular control. HPB Surg. 2012;2012:720754.
15. Chouillard EK, Gumbos AA, Cherqui D. Vascular clamping in liver surgery: physiology, indications and techniques. Ann Surg Innov Res. 2010;4:1–12.
16. Smyrniotis V, Farantos C, Kostopanagiotou G, Arkadopoulos N. Vascular control during hepatectomy: review of methods and results. World J Surg. 2005;29:1384–1396.
17. Scatton O, Brustia R, Belli G, Pekolj J, Wakabayashi G, Gayet B. What kind of energy devices should be used for laparoscopic liver resection? Recommendations from a systematic review. J Hepatobiliary Pancreat Sci. 2015;22:327–334.
18. Huntington JT, Royall NA, Schmidt CR. Minimizing blood loss during hepatectomy: a literature review. J Surg Oncol. 2014;109:81–88.
19. Boonstra EA, Molenaar IQ, Porte RJ, de Boer MT. Topical haemostatic agents in liver surgery: do we need them? HPB (Oxford). 2009;11:306–310.
20. Hanna EM, Martinie JB, Swan RZ, Iannitti DA. Fibrin sealants and topical agents in hepatobiliary and pancreatic surgery: a critical appraisal. Langenbecks Arch Surg. 2014;399:825–835.
21. Sanjay P, Watt DG, Wigmore SJ. Systematic review and meta-analysis of haemostatic and biliostatic efficacy of fibrin sealants in elective liver surgery. J Gastrointest Surg. 2013;17:829–836.
22. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6: e1000100.
23. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926.
24. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–412.
25. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609–613.
26. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
27. Bektas H, Nadalin S, Szabo I, Ploder B, Sharkhawy M, Schmidt J. Hemostatic efficacy of latest-generation fibrin sealant after hepatic resection: a randomized controlled clinical study. Langenbecks Arch Surg. 2014;399:837–847.
28. Bochicchio GV, Gupta N, Porte RJ, Renkens KL, Pattyn P, Topal B, et al. The FINISH-3 trial: a phase 3, international, randomized, single-blind, controlled trial of topical fibrocaps in intraoperative surgical hemostasis. J Am Coll Surg. 2015;220:70–81.
29. Briceño J, Naranjo A, Ciria R, Díaz-Nieto R, Sánchez-Hidalgo JM, Luque A, et al. A prospective study of the efficacy of clinical application of a new carrier-bound fibrin sealant after liver resection. Arch Surg. 2010;145:482–488.
30. Cauchy F, Gaujoux S, Ronot M, Fuks D, Dokmak S, Sauvanet A, et al. Local venous thrombotic risk of an expanding haemostatic agent used during liver resection. World J Surg. 2014;38:2363–2369.
31. Chapman WC, Clavien PA, Fung J, Khanna A, Bonham A. Effective control of hepatic bleeding with a novel collagen-based composite combined with autologous plasma: results of a randomized controlled trial. Arch Surg. 2000;135:1200–1204.
32. de Boer MT, Klaase JM, Verhoef C, van Dam RM, van Gulik TM, Molenaar IQ, et al. Fibrin sealant for prevention of resection surface-related complications after liver resection: a randomized controlled trial. Ann Surg. 2012;256:229–234.
33. Figueras J, Llado L, Miro M, Ramos E, Torras J, Fabregat J, et al. Application of fibrin glue sealant after hepatectomy does not seem justified: results of a randomized study in 300 patients. Ann Surg. 2007;245:536–542.
34. Fischer L, Seiler CM, Broelsch CE, de Hemptinne B, Klempnauer J, Mischinger HJ, et al. Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial. Surgery. 2011;149:48–55.
35. Frilling A, Stavrou GA, Mischinger HJ, de Hemptinne B, Rokkjaer M, Klempnauer J, et al. Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial. Langenbecks Arch Surg. 2005;390:114–120.
36. Genyk Y, Kato T, Pomposelli JJ, Wright JK Jr, Sher LS, Tetens V, et al. Fibrin Sealant Patch (TachoSil) vs Oxidized Regenerated Cellulose Patch (Surgicel Original) for the Secondary Treatment of Local Bleeding in Patients Undergoing Hepatic Resection: A Randomized Controlled Trial. J Am Coll Surg. 2015;18. pii: S1072-7515(15)01777-9.
37. Gugenheim J, Bredt LC, Iannelli A. A randomized controlled trial comparing fibrin glue and PlasmaJet on the raw surface of the liver after hepatic resection. Hepatogastroenterology. 2011;58:922–925.
38. Hayashibe A, Sakamoto K, Shinbo M, Makimoto S, Nakamoto T. New method for prevention of bile leakage after hepatic resection. J Surg Oncol. 2006;94:57–60.
39. Kobayashi S, Nagano H, Marubashi S, Wada H, Eguchi H, Tanemura M, et al. Experience with the use of fibrin sealant plus polyglycolic acid felt at the cut surface of the liver in laparoscopic hepatectomy. Surg Endosc. 2011;25:3590–3596.
40. Kobayashi S, Nagano H, Marubashi S, Wada H, Eguchi H, Takeda Y, et al. Fibrin sealant with PGA felt for prevention of bile leakage after liver resection. Hepatogastroenterology. 2012;59:2564–2568.
41. Koea JB, Batiller J, Patel B, Shen J, Hammond J, Hart J, et al. A phase III, randomized, controlled, superiority trial evaluating the fibrin pad versus standard of care in controlling parenchymal bleeding during elective hepatic surgery. HPB (Oxford). 2013;15:61–70.
42. Liu M, Lui WY. The use of fibrin adhesive for hemostasis after liver resection. Zhonghua Yi Xue Za Zhi (Taipei). 1993;51:19–22.
43. Moench C, Mihaljevic AL, Hermanutz V, Thasler WE, Suna K, Diener MK, et al. Randomized controlled multicenter trial on the effectiveness of the collagen hemostat Sangustop® compared with a carrier-bound fibrin sealant during liver resection (ESSCALIVER study, NCT00918619). Langenbecks Arch Surg. 2014;399:725–733.
44. Ollinger R, Mihaljevic AL, Schuhmacher C, Bektas H, Vondran F, Kleine M, et al. A multicentre, randomized clinical trial comparing the Veriset haemostatic patch with fibrin sealant for the management of bleeding during hepatic surgery. HPB (Oxford). 2013;15:548–558.
45. Schwartz M, Madariaga J, Hirose R, Shaver TR, Sher L, Chari R, et al. Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg. 2004;139:1148–1154.
46. Toti L, Attia M, Manzia TM, Lenci I, Gunson B, Buckels JA, et al. Reduction in bile leaks following adult split liver transplant using a fibrin-collagen sponge: a pilot study. Dig Liver Dis. 2010;42:205–209.
47. Verhoef C, Singla N, Moneta G, Muir W, Rijken A, Lockstadt H, et al. Fibrocaps for surgical hemostasis: two randomized, controlled phase II trials. J Surg Res. 2015;194:679–687.
48. Zacharias T, Ferreira N. Carrier-bound fibrin sealant compared to oxidized cellulose application after liver resection. HPB (Oxford). 2012;14:839–847.
49. Corral M, Ferko N, Hollmann S, Hogan A, Jamous N, Batiller J, et al. Clinician reported ease of use for a novel fibrin sealant patch for hemostasis: results from four randomized controlled trials. Curr Med Res Opin. 2016;32:367–375.